Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.61 |
| ▸ | HTR2A | P28223 | 12/20 | 0.61 |
| ▸ | HTR2B | P41595 | 10/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415399 | 0.89 | HTR2C (0.63) | HTR2CHTR2AHTR2BEPHA2KDR | |
| SCHEMBL6408213 | 0.86 | HTR2C (0.55) | HTR2CHTR2AHTR2BEPHA2KDR | |
| SCHEMBL6410846 | 0.85 | EPHA2 (0.48) | HTR2CHTR2AHTR2BEPHA2KDR | |
| SCHEMBL6408467 | 0.81 | HTR2A (0.58) | HTR2CHTR2AHTR2BEPHA2KDR | |
| SCHEMBL6410204 | 0.80 | HTR2C (0.49) | HTR2CHTR2AHTR2B | |
| SCHEMBL7092826 | 0.78 | MCHR1 (0.50) | HTR2CHTR2AHTR2B | |
| SCHEMBL6413627 | 0.78 | UTS2R (0.57) | HTR2CHTR2AKDREGFR | |
| SCHEMBL6408932 | 0.76 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRA1DADRA1A | |
| SCHEMBL906652 | 0.75 | KDR (1.00) | EPHA2KDREPHB4EGFR | |
| SCHEMBL13946676 | 0.74 | HTR2A (0.50) | HTR2CHTR2AHTR2BEPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1465630-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | HTR2C 1/4885HTR2A 30/4885HTR2B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.